Lemonaid Health works with state-licensed compounding pharmacies to offer compounded semaglutide
What 503A Compounding Pharmacies Currently Cannot Make These widely used clinical peptides are not eligible for 503A compounding under current rules: BPC-157 (Body Protective Compound, used for tendon, ligament, and gut-lining repair) TB-500 / Thymosin Beta-4 fragment (recovery and inflammation modulation) CJC-1295 (GHRH analog, used for growth hormone optimization) Ipamorelin (selective GH secretagogue) MOTS-c (mitochondrial-derived peptide, metabolic and longevity research) Epithalon (Epitalon) (telomere-supporting longevity peptide) Semax (cognitive and neuroprotective peptide) GHK-Cu (copper tripeptide for skin and tissue regeneration) AOD-9604 (modified fragment of growth hormone, studied for fat metabolism) These peptides are widely studied
In response to the proposal in the CY 2023 PFS proposed rule to increase the data completeness criteria threshold to at least 80 percent starting with the CY 2026 performance period/2028 MIPS payment year, interested parties indicated in the public comments that increasing the data completeness threshold from 75 to 80 percent within two years of increasing the threshold from 70 to 75 percent would present various challenges such as the following, which would make it more difficult to meet the data completeness criteria threshold: increased burden (in particular, disproportionately increase burden for smaller and rural practices due to limited resources and staff, and some practices that are continuing to recover from the COVID-19 Public Health Emergency)
Mol Neurobiol 58:17691781
Its amino acid sequence and structural characteristics provide some resistance to degradation
